Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Suzhou City, China Clinical Trials

A listing of Suzhou City, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (6) clinical trials

CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia

CNS leukemia is defined as unequivocal evidence of leukemic blasts in the cerebrospinal fluid by cytology or flow cytometry; cranial palsies or a nonhemorrhagic mass seen in cranial computed tomography or magnetic resonance imaging because of infiltration by leukemia cells

Phase

0.0 miles

Learn More »

A Study Evaluating Drug-Drug Interaction (DDI) Between HSK3486 Injectable Emulsion and Voriconazole Tablets

After the recruited healthy subjects passed the screening of inclusion and exclusion criteria, a seed number was set in the PLAN program of the SAS 9.4 software by the statistician before the formal enrollment, and the subject screening numbers were randomly assigned to the two groups by using a 1:1 …

Phase

0.0 miles

Learn More »

Functional Neural Regeneration Collagen Scaffold Transplantation in Acute Spinal Cord Injury Patients

The study is designed to assess the safety and efficacy of functional neural regeneration collagen scaffold transplanted into acute spinal cord injury patients.

Phase

3.13 miles

Learn More »

A Study of Belantamab Mafodotin to Investigate Safety Tolerability Pharmacokinetics Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Multiple myeloma (MM) is a neoplastic plasma cell disorder that is characterized by osteolytic bone lesions, anemia, hypercalcemia and renal failure. belantamab mafodotin was well tolerated in previous studies with at least one dose of belantamab mafodotin in heavily pre-treated participants with relapsed/refractory multiple myeloma (RRMM). This aim of the …

Phase

3.13 miles

Learn More »

SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors

This is a Phase I, open-label, multiple-ascending dose trial. Study consists of dose-escalation part in subjects with metastatic or locally advanced solid tumors, and expansion part with selected indications.

Phase

3.13 miles

Learn More »

A Study of MSB2311 in Advanced Solid Tumors

This is a first-in-human (FIH), open-label, Phase 1 dose-Escalation Study of MSB2311, a humanized anti-PD-L1 monoclonal antibody, in subjects with advanced solid tumors. Qualified subjects will be enrolled to receive their assigned dose regimen of MSB2311 until disease progression or intolerable toxicity, withdrawal of consent, or end of study, whichever …

Phase

9.68 miles

Learn More »